Andile H. Ngwane

A Novel Inhibitor of Gyrase B Is a Potent Drug Candidate for Treatment of Tuberculosis and Nontuberculosis Mycobacterial Infections

Christopher P. Locher, Steven M. Jones, Brian L. Hanzelka et al. · Antimicrobial Agents and Chemotherapy · 2014 · 81 citations · Full text

Medicine, Infectious Diseases, Pharmacology +14

Synthesis, antimycobacterial evaluation and pharmacophore modeling of analogues of the natural product formononetin

Peggoty Mutai, Elumalai Pavadai, Ian Wiid et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 43 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Topical Delivery of Artemisone, Clofazimine and Decoquinate Encapsulated in Vesicles and Their In vitro Efficacy Against Mycobacterium tuberculosis

Lindi van Zyl, Joe M. Viljoen, Richard K. Haynes et al. · AAPS PharmSciTech · 2019 · 42 citations

Pharmacy, Infectious Diseases, Pharmaceutics +11

Sulfamethoxazole enhances the antimycobacterial activity of rifampicin

Lubabalo Macingwana, Bienyameen Baker, Andile H. Ngwane et al. · Journal of Antimicrobial Chemotherapy · 2012 · 30 citations

Medicine, Pharmacology, Pharmacotherapy +14

The evaluation of the anti‐cancer drug elesclomol that forms a redox‐active copper chelate as a potential anti‐tubercular drug

Andile H. Ngwane, Ray‐Dean Petersen, Bienyameen Baker et al. · IUBMB Life · 2019 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13